{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
| image = Lonaprisan skeletal.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 211254-73-8
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 6918548
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 5293745
| UNII = F5Z5EL4D26
| KEGG = D10016
| ChEBI = 
| ChEMBL = 146032

<!--Chemical data-->
| C=28 | H=29 | F=5 | O=3
| molecular_weight = 508.529 g/mol
| SMILES = CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C(C(F)(F)F)(F)F)O)[C@H]4C2=C5CCC(=O)C=C5CC4)C
| StdInChI_Ref = 
| StdInChI = 1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = VHZPUDNSVGRVMB-RXDLHWJPSA-N
| synonyms = ZK-230211; BAY 86-5044; ZK-PRA; 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one
}}

'''Lonaprisan''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code names '''ZK-230211''', '''BAY 86-5044''', '''ZK-PRA''') is a [[synthetic compound|synthetic]], [[steroid]]al [[antiprogestogen]] which was under development by [[Bayer|Bayer HealthCare Pharmaceuticals]] for the treatment of [[endometriosis]], [[dysmenorrhea]], and [[breast cancer]] but was discontinued.<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800017206</ref><ref name="pmid24950125">{{cite journal | vauthors = Whitaker LH, Williams AR, Critchley HO | title = Selective progesterone receptor modulators | journal = Curr. Opin. Obstet. Gynecol. | volume = 26 | issue = 4 | pages = 237–42 | year = 2014 | pmid = 24950125 | doi = 10.1097/GCO.0000000000000082 | url = }}</ref><ref name="pmid26645363">{{cite journal | vauthors = Pluchino N, Freschi L, Wenger JM, Streuli I | title = Innovations in classical hormonal targets for endometriosis | journal = Expert Rev Clin Pharmacol | volume = 9 | issue = 2 | pages = 317–27 | year = 2016 | pmid = 26645363 | doi = 10.1586/17512433.2016.1129895 | url = }}</ref> It is a [[potency (pharmacology)|potent]] and highly [[binding selectivity|selective]] [[silent antagonist]] of the [[progesterone receptor]] (PR).<ref name="pmid24950125" /><ref name="pmid26645363" /><ref name="pmid21138753">{{cite journal | vauthors = Busia L, Faus H, Hoffmann J, Haendler B | title = The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression | journal = Mol. Cell. Endocrinol. | volume = 333 | issue = 1 | pages = 37–46 | year = 2011 | pmid = 21138753 | doi = 10.1016/j.mce.2010.11.034 | url = }}</ref> The drug reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s prior to its discontinuation.<ref name="AdisInsight" />

==See also==
* [[Mifepristone]]
* [[Onapristone]]
* [[Ulipristal acetate]]
* [[Vilaprisan]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800017206 Lonaprisan - AdisInsight]


{{Progesterone receptor modulators}}

[[Category:Alcohols]]
[[Category:Antiprogestogens]]
[[Category:Diketones]]
[[Category:Organofluorides]]


{{steroid-stub}}
{{genito-urinary-drug-stub}}